Conatus Pharmaceuticals (CNAT-$6.03) is developing a first-in-class, orally active pan-caspase
protease inhibitor, called emricasan, which is designed to
reduce the activity of the caspase family of related enzymes that mediate
inflammation (measured as serum ALT) and cell death, or apoptosis (measured as
biomarker cCK18).
It is postulated that by inhibiting
hepatocyte apoptosis and subsequent profibrogenic activity, emricasan’s dual
mechanism of action could offer a viable therapeutic option to slow progression
across the entire spectrum of fibrotic liver disease(s).
The share price of CNAT has
slipped some 35% from its summer high of $9.48 a share, due to a pullback in
small capitalization stock valuations and an announced delay for release of topline
results from a pivotal NASH trial.
To read about possible upside,
value-creating catalysts at CNAT, subscribe to PropThink.com, one of the
top-rated biotech stock blogs: WHY CONATUS FELL OUT OF BED IN THE
SECOND HALF
No comments:
Post a Comment